Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Inclusion Criteria:

* Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

  * Recurrent or persistent after initial standard surgery or chemotherapy
  * Incurable with standard surgery, chemotherapy, or radiotherapy
* At least 1 unidimensionally measurable target lesion

  * At least 20 mm by conventional techniques
  * At least 10 mm by spiral CT scan
  * Outside the area of prior radiotherapy
* Accessible to guided core needle biopsy
* Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin, or another organoplatinum compound) for primary disease

  * May have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
  * Patients with only 1 prior platinum-based chemotherapy regimen must have an initial treatment-free interval of less than 12 months
  * Patients with an initial treatment-free interval of more than 12 months must have progressive disease after prior platinum-based chemotherapy regimen as second-line therapy
* No tumors involving major blood vessels
* No evidence of CNS disease (primary brain tumor or brain metastases) within the past 5 years
* Ineligible for higher priority Gynecologic Oncology Group (GOG) protocols (i.e., active phase III GOG protocols for the same patient population)
* Performance status - GOG 0-2 (patients who have received 1 prior regimen)
* Performance status - GOG 0-1 (patients who have received 2 prior regimens)
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* No known bleeding disorder or coagulopathy
* No active bleeding
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* serum glutamate oxaloacetate transaminase (SGOT) ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* PT (INR) ≤ 1.5 (INR 2-3 if on stable dose of therapeutic warfarin or low molecular weight heparin)
* Partial thromboplastin time (PTT) \< 1.2 times control
* Creatinine ≤ 1.5 times ULN
* Creatinine clearance \> 60 mL/min
* No proteinuria, as indicated by 1 of the following:

  * Negative urine dipstick
  * Urine protein \< 30 mg/dL
  * Urine protein \< 1,000 mg on 24-hour urine collection
* No clinically significant cardiovascular disease, including any of the following:

  * Uncontrolled hypertension
  * Myocardial infarction within the past 6 months
  * Unstable angina within the past 6 months
  * New York Heart Association class II-IV congestive heart failure
  * Serious cardiac arrhythmia requiring medication
  * Peripheral vascular disease ≥ grade 2
* No stroke within the past 5 years
* No pathologic condition that carries a high risk of bleeding
* No significant traumatic injury within the past 28 days
* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
* No uncontrolled seizures within the past 5 years
* No neuropathy (motor and sensory) ≥ grade 2
* No serious non-healing wound, ulcer, or bone fracture
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
* No active infection requiring parenteral antibiotics
* No known claustrophobia that would preclude MRI tolerance
* No ferromagnetic implants or pacers
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for at least 3 months after study treatment
* At least 3 weeks since prior immunologic therapy directed at malignancy
* No prior bevacizumab
* No other concurrent immunotherapy directed at malignancy
* One additional prior cytotoxic regimen for recurrent or persistent disease allowed
* No prior non-cytotoxic chemotherapy for recurrent or persistent disease
* No concurrent chemotherapy directed at malignancy
* At least 1 week since prior hormonal therapy directed at malignancy
* No concurrent hormonal therapy directed at malignancy
* Concurrent hormone replacement therapy allowed
* Recovered from prior radiotherapy
* No concurrent radiotherapy directed at malignancy
* At least 28 days since prior major surgery or open biopsy and recovered
* At least 7 days since prior core biopsy or placement of vascular access device
* No anticipated need for major surgical procedure during study participation
* At least 3 weeks since other prior therapy directed at malignancy
* No prior anticancer therapy that would preclude study entry